Randomized phase II study of aprepitant in patients with colorectal cancer receiving FOLFOX, FOLFIRI, or XELOX chemotherapy regimen.
收藏NIAID Data Ecosystem2026-03-07 收录
官方服务：
资源简介：
Interventions: Aprepitant; 125 mg PO on day 1 Aprepitant; 80 mg PO on days 2 to 3 5HT3-receptor antagonist; IV on day 1 Dexamethasone; 6.6 mg IV on day 1 Dexamethasone; 4 mg PO on days 2 to 3 5HT3-receptor antagonist; IV on day 1 Dexamethasone; 9.9 mg IV on day 1 Dexamethasone; 8 mg PO on days 2 to 3 Primary outcome(s): The percentage of patients with complete response (defined as no emetic episode and no rescue therapy) Study Design: Parallel Randomized
创建时间：
2011-11-15
